BeiGene's Brukinsa PFS Win Lifts China Biotech Stocks
Bests Imbruvica In CLL
BeiGene's Brukinsa beats Imbruvica in top-line progression-free survival results from the Phase III head-to-head ALPINE trial in chronic lymphocytic leukemia or small lymphocytic lymphoma, marking the first time a rival BTK inhibitor has bested the same-class standard of care in this setting, and lifting the shares of other Chinese biotechs.
